Clinical Trial

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Protocol Amendment History 64 amendments
This ClinicalTrials.gov record has been amended 64 times since 2022-12-25; most recent amendment 2025-11-26.
Status change: Recruiting → Active, Not Recruiting 2025-11-26
Trial Details
NCT Number NCT05681351
Lead Sponsor Ionis Pharmaceuticals, Inc.
Conditions Severe Hypertriglyceridemia
Enrollment 885 participants
Start Date 2022-12-13
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-01